US · Healthcare · Diagnostics & Research
EPS came in at -0.89 against a street estimate of -0.74 — a miss of 20.3%.
Analysts rate Guardant Health Inc a strong buy (22 buy, 0 hold, 1 sell out of 23) with an average price target of $194.29.
CONFIDENT GH delivered $335M revenue (+44% YoY) across oncology, screening, and biopharma. FDA approved Guardant360 Liquid CDx and lower-COGS Shield workflow. UnitedHealth coverage and ACS guidelines unlock 70M lives in screening market. Q2 2026 No geographic breakdown provided. Analysts pressed on UnitedHealth's surprise coverage timing, ADLT pricing uplift mechanics, and timing of Reveal MolDX approvals. Management emphasized surprise nature of UnitedHealth win, guided to ADLT $8,455 pricing yielding ~$5K Guardant360 ASP over 12–24 months, and reiterated hopeful timing for Reveal breast/IO by year-end without guarantees. 2026-07-30…
Full summary in the app.
| Fund | Stake |
|---|---|
| BlackRock Inc | 8.61% |
| T. Rowe Price Associates, Inc. | 5.23% |
| Vanguard Portfolio Management, LLC | 4.35% |
| Vanguard Capital Management, LLC | 4.19% |
| Amvescap Plc. | 3.69% |
| The Goldman Sachs Group Inc | 3.31% |
| Two Sigma Investments LLC | 3.15% |
| FMR Inc | 3.07% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 GUARDANT HEALTH, INC. — Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Q2 2026 revenue: $334.98 million (vs. $232.09 million in Q2 2025) — 44% year-over-ye | 2026-07-30 |
| Results announced · Q3 2026 GUARDANT HEALTH Q2 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Q2 2026 revenue: $335.0 million (44% increase year-over-year from $232.1 million in Q2 | 2026-07-30 |
| Shareholder vote results · Q2 2026 GUARDANT HEALTH, INC. - 8-K SUMMARY HEADLINE NUMBERS • Annual stockholder meeting held June 17, 2026 • Total votes cast across proposals: approximat | 2026-06-18 |
| Quarterly report · Q1 2026 GUARDANT HEALTH, INC. – Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Revenue: $301.7 million (Q1 2026) vs. $203.5 million (Q1 2025) – 48% year-over-year | 2026-05-07 |
| Results announced · Q2 2026 GUARDANT HEALTH Q1 2026 FINANCIAL RESULTS HEADLINE NUMBERS • Q1 2026 Total Revenue: $301.7 million, up 48% year-over-year (Q1 2025: $203.5 million) | 2026-05-07 |
| Proxy statement · Q2 2026 GUARDANT HEALTH, INC. – 2026 PROXY STATEMENT SUMMARY --- CEO COMPENSATION • Helmy Eltoukhy (Co-CEO) 2025 Total Compensation: $19,411,597 (exact amo | 2026-04-28 |
| Board / officer change · Q2 2026 GUARDANT HEALTH, INC. – 8-K SUMMARY HEADLINE NUMBERS • Filing Date: April 27, 2026 • Company: Guardant Health, Inc. (ticker: GH, NASDAQ) • Headquart | 2026-04-27 |
| Annual report FY2025 GUARDANT HEALTH, INC. — 2025 FORM 10-K SUMMARY HEADLINE NUMBERS • Company is Guardant Health, Inc., a precision oncology company based in Palo Alto, | 2026-02-19 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Guardant Health Inc — free to start.
Google PlayApp StoreData updated 2026-09-18.